Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes
The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in subjects with diabetic kidney disease (DKD), albeit with a large variability between individuals. Identifying novel biomarkers that predict response to therapy may help to tailor spironolactone therapy. We aimed to identify a set of metabolites for prediction of albuminuria response to spironolactone in subjects with type 2 diabetes. Systems biology molecular process analysis was performed a priori to identify metabolites linked to molecular disease processes and drug mechanism of action.
Source: Translational Research - Category: Research Authors: Skander Mulder, Paul Perco, Christina Oxlund, Uzma F. Mehdi, Thomas Hankemeier, Ib A. Jacobsen, Robert Toto, Hiddo J.L. Heerspink, Michelle J. Pena Source Type: research
More News: Biology | Diabetes | Diabetes Type 2 | Endocrinology | Molecular Biology | Research | Spironolactone | Urology & Nephrology